Traws Pharma, Inc.
TRAWNASDAQHealthcare● Active
$1.37
+$0.00(+0.00%)
Market Cap$12522441
P/E Ratio—
52W High$3.27
52W Low$1
Traws Pharma, Inc. (TRAW) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TRAW · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.53
Est. -$0.92 · +42.4%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS🔥 6-Quarter EPS Beat Streak
TRAW reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.52
Rev. $3.34B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.52
Rev. Est.$3.34B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.81 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.92 | -$0.53 | +42.4% | — | $0.00B | — |
| ▲ Q2 FY2026 | Apr 15, 2026 | -$1.22 | -$0.71 | +42.0% | — | $0.00B | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$8.75 | -$0.11 | +98.7% | $0.00B | $0.00B | +4455.0% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$8.75 | -$0.11 | +98.7% | $0.00B | $0.00B | +4455.0% |
| ▲ Q2 FY2025 | May 15, 2025 | -$8.04 | $2.09 | +126.0% | $0.00B | $0.00B | -5.0% |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$9.55 | $95.66 | +1101.7% | $0.00B | $0.00B | -6.7% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$6.25 | -$8.81 | -41.0% | $0.00B | $0.00B | -6.7% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.81
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.53
EPS Est.
-$0.92
EPS Surpr.
+42.4%
Revenue
—
Q2 FY2026
Apr 15, 2026Beat
EPS Actual
-$0.71
EPS Est.
-$1.22
EPS Surpr.
+42.0%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$8.75
EPS Surpr.
+98.7%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$8.75
EPS Surpr.
+98.7%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Beat
EPS Actual
$2.09
EPS Est.
-$8.04
EPS Surpr.
+126.0%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
$95.66
EPS Est.
-$9.55
EPS Surpr.
+1101.7%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$8.81
EPS Est.
-$6.25
EPS Surpr.
-41.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $-1.16 | $-1.16 | $-1.16 | 1 |
| Q1 FY2027 | $-0.95 | $-0.95 | $-0.95 | 1 |
| Q3 FY2026 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Q1 FY2026 | $-0.81 | $-0.81 | $-0.81 | 1 |
| Q3 FY2025 | $-1.22 | $-1.22 | $-1.22 | 1 |
| Q1 FY2025 | $-8.75 | $-8.75 | $-8.75 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +42.4% | $1.63 | $1.88 | +15.34% |
| ▲ Q2 FY2026 | Apr 15, 2026 | +42.0% | $1.59 | $1.23 | -22.64% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +98.7% | $1.64 | $1.62 | -1.22% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +98.7% | $1.64 | $1.62 | -1.22% |
| ▲ Q2 FY2025 | May 15, 2025 | +126.0% | $1.24 | $1.10 | -11.29% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +1101.7% | $2.40 | $2.30 | -4.17% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -41.0% | $5.65 | $5.58 | -1.24% |
| ▼ Q3 FY2024 | Aug 15, 2024 | -1848.0% | $8.58 | $9.00 | +4.90% |
Q2 FY2026+15.34%
Report Date
May 15, 2026
EPS Beat/Miss
+42.4%
Price Before
$1.63
Price After
$1.88
Q2 FY2026-22.64%
Report Date
Apr 15, 2026
EPS Beat/Miss
+42.0%
Price Before
$1.59
Price After
$1.23
Q3 FY2025-1.22%
Report Date
Aug 14, 2025
EPS Beat/Miss
+98.7%
Price Before
$1.64
Price After
$1.62
Q3 FY2025-1.22%
Report Date
Aug 14, 2025
EPS Beat/Miss
+98.7%
Price Before
$1.64
Price After
$1.62
Q2 FY2025-11.29%
Report Date
May 15, 2025
EPS Beat/Miss
+126.0%
Price Before
$1.24
Price After
$1.10
Q1 FY2025-4.17%
Report Date
Mar 31, 2025
EPS Beat/Miss
+1101.7%
Price Before
$2.40
Price After
$2.30
Q4 FY2024-1.24%
Report Date
Nov 14, 2024
EPS Beat/Miss
-41.0%
Price Before
$5.65
Price After
$5.58
Q3 FY2024+4.90%
Report Date
Aug 15, 2024
EPS Beat/Miss
-1848.0%
Price Before
$8.58
Price After
$9.00
Avg Beat Reaction-4.20%
Avg Miss Reaction+1.83%
Beat Rate6 / 8 quarters
Largest Move-22.64% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TRAW ends December
Traws Pharma, Inc. (TRAW) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.53 — beating the analyst consensus of $-0.92 by +42.4%. TRAW has beaten EPS estimates for 6 consecutive quarters. The next TRAW earnings date is expected around September 1, 2026.
Each quarter, investors track TRAW earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TRAW revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TRAW's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TRAW earnings · 5 questionsTraws Pharma, Inc.'s next earnings report is expected around September 1, 2026. TRAW typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TRAW historically reports after market close (AMC).
TRAW earnings datewhen is TRAW earningsTRAW next earnings datewhen does TRAW report earningsTRAW earnings calendar
▸ Source: FMP · Traws Pharma, Inc. SEC filings · US GAAP · Traws Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026